GINA CROSS: Open Payments
NPI 1124387915 · CHARLEROI, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,395 in 119 payments from 17 companies in 2025. Trend: 2023 $2,557 · 2024 $3,079 · 2025 $2,395
Food & beverage: $2,298Education: $97
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 16 | $364 |
| Travere Therapeutics, Inc. | 15 | $305 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $273 |
| AstraZeneca Pharmaceuticals LP | 11 | $253 |
| Novartis Pharmaceuticals Corporation | 10 | $223 |
| Calliditas Therapeutics US Inc. | 13 | $204 |
| Otsuka America Pharmaceutical, Inc. | 8 | $183 |
| Ardelyx, Inc. | 9 | $144 |
| Vifor Pharma, Inc. | 10 | $139 |
| OPKO Pharmaceuticals, LLC | 5 | $97 |
Products named: JARDIANCE, Kerendia, FARXIGA, TARPEYO, IBSRELA, Veltassa, JYNARQUE, Vanrafia.
Industry payments across PA — which companies pay providers there.
